Jan Aushadhi Kendras Achieve Sales Exceeding Rs 1,255 Crores by November: PMO
Click to start listening
New Delhi, Jan 7 (NationPress) The Jan Aushadhi centers have recorded sales exceeding Rs 1,255 crore in medicines up to November, according to the statement from the Prime Minister’s Office on Tuesday.
In a post on the social media platform X, the PMO highlighted that purchasing medicines from these centers resulted in savings of approximately Rs 5,020 crore for the public.
“Jan Aushadhi outlets have crossed Rs 1,255 crore in sales by the end of November, providing benefits worth Rs 5,000 crore to the citizens,” stated the PMO.
The Jan Aushadhi Kendras are specialized centers aimed at offering quality medications at affordable rates to the general public. Established under the Pradhan Mantri Bharatiya Janaushadhi Pariyojana (PMBJP), a public welfare initiative, this program was launched in November 2008.
The implementation of the scheme is overseen by the Pharmaceuticals & Medical Devices Bureau of India (PMBI).
As of November 2024, the Ministry of Chemicals and Fertilizers reported that a total of 14,320 Jan Aushadhi Kendras have been established across the country.
For the fiscal year 2023-24, the PMBI, operating under the Department of Pharmaceuticals, reported sales of Rs 1,470 crore, resulting in savings of around Rs 7,350 crore for the populace.
Over the past decade, it is estimated that approximately Rs 30,000 crore has been saved through this Pariyojana.
In 2024, the PMBJP also entered into several Memoranda of Understanding (MoUs) with Central Armed Police Forces, National Security Guard & Assam Rifles (CAPFs, NSG & AR) to enhance healthcare access by providing Jan Aushadhi medicines to CAPFs, NSG & AR (MHA) hospitals.
Additionally, the first international Jan Aushadhi Kendra was inaugurated in Mauritius.
The Department of Pharmaceuticals has also initiated a program in the current fiscal year aimed at strengthening the pharmaceutical sector with a total budget of Rs 500 crore, as stated by the ministry.
This program is designed to support existing pharmaceutical clusters and MSMEs throughout the nation to boost their productivity, quality, and efficiency.
